duodenal ulcer

Roxatidine Acetate hydrochloride (HOE 760) is a specific and competitive histamin H2-receptor antagonist. It inhibits gastric acid secretion and ulcer formation.

Rebamipide (OPC12759) is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.

Cyclic somatostatin (SRIF-14) is a cyclic tetradecapeptide that regulates various endocrine and nervous system functions.

Ilaprazole (IY-81149) is a proton pump inhibitor used in the treatment of dyspepsia gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. Studies also showed that Ilaprazole significantly prevented the development of reflux oesophagitis.

KB 5492 is an agent of anti-ulcer. It preventing cysteamine-induced duodenal ulcers by stimulating duodenal HCO3- secretion.

Roxatidine hydrochloride is an anti-ulcer agent and histamine antagonist that suppresses gastric acid secretion. It effectively heals duodenal and gastric ulcers and reduces ulcer pain. Roxatidine acetate has an improved safety profile compared to other similar drugs, in part because lower doses of roxatidine acetate are therapeutically effective.

Zolimidine, an imidazopyridine derivative, functions as an orally active antiulcer agent. It promotes mucus secretion in intestinal mucosal cells and enhances the intestinal wall's resistance to ulceration. Studies demonstrate its gastroprotective effect in duodenal ulcer research [1] [2].